(Q85646462)
Statements
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801) (English)
Daniel Castellano
Jaume Capdevila
Javier Sastre
Vicente Alonso
Marta Llanos
José Luis Manzano Mozo
Isabel Sevilla
Ignacio Durán
5 September 2013